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ABSTRACT 
Background: In the treatment of hypertension, combination therapy is im- 
portant because antihypertensive monotherapy is effective in only 40% of pa- 
tients worldwide. Amlodipine is a dihydropyridine calcium channel blocker with a 
slow onset and long duration of action. Benazepril hydrochloride is a prodrug 
hydrolyzed by esterase to the active metabolite benazeprilat, an angiotensin- 
converting enzyme inhibitor. In 1995, the US Food and Drug Administration ap- 
proved the use of a capsule formulation of combination amlodipine-benazepril 
for hypertension. 
Objective: The aim of this study was to compare the bioavailability and tol- 
erability of the capsule formulation with those of a tablet formulation of combi- 
nation amlodipine-benazepril in healthy volunteers. 
Methods: This single-dose, 2-sequence, 2-period, open-label, crossover 
study recruited healthy, adult, male volunteers with normotension. Subjects 
were randomly assigned to 1 of 2 treatment sequences: a single-dose tablet con- 
taining amlodipine 5 mg plus benazepril 10 mg, followed by a single-dose cap- 
sule containing the same dose of each drug (AB), or vice versa (BA). The treat- 
ment period for each drug consisted of dosing and pharmacokinetic analysis on 
day 1, followed by pharmacokinetic analysis on days 2 to 7. Treatment periods 
were separated by a 4-week washout period. For pharmacokinetic analysis, serial 
blood samples were obtained before dosing and at 20, 40, 60, 80, and 100 minutes 
and 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 60, 84, 108, 132, and 156 hours after dosing. 
Tolerability was assessed using subject interview and spontaneous reporting. 
Results: Twelve healthy, male, Taiwanese subjects (mean [SD] age, 23.5 
[1.7] years) participated in the study. No statistically significant differences in 
bioavailability were found between the 2 formulations based on the pharmaco- 
kinetic measurements of amlodipine and benazeprilat. The rate and extent of 
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absorption of the tablets were found to be comparable to those of the capsules 
(90% CI, between 80% and 125%). The mean (SD) relative bioavailabilities, 
as represented by AUC0_o~, of amlodipine and benazeprilat for tablets versus 
capsules were 1.060 (0.170) versus 0.949 (0.197), respectively. The mean plasma 
concentration-time profiles of amlodipine and benazeprilat were graphically 
similar. No adverse ffects were observed with either formulation. 
Conclusions: The results of this bioavailability comparison study in this 
population of healthy, male, Taiwanese volunteers uggest that the tablet and 
capsule formulations of combination amlodipine-benazepril a ebioequivalent. 
Both formulations were well tolerated. (Curt Ther Res Clin Exp. 2005;66:69-79) 
Copyright © 2005 Excerpta Medica, Inc. 
Key words: bioequivalence, bioavailability, pharmacokinetics, amlodipine 
besylate, benazepril hydrochloride, fixed-dose combination. 
INTRODUCTION 
In the treatment of hypertension, combination therapy is important because 
antihypertensive monotherapy is effective in only 40% of patients worldwide.1 
Products containing a combination of 2 classes of antihypertensive drugs 
(eg, a calcium channel blocker [CCB] and an angiotensin-converting e zyme 
inhibitor [ACEI]) result in synergistic effects on blood pressure control and 
vital-organ protection, and decrease the risk for adverse effects (AEs). The 
Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure 2 also recommends combination 
therapy. 
Among various combinations, those containing a CCB plus an ACEI are pre- 
scribed most often. 3-5 Long-acting CCB-ACEI combination therapy (eg, amlodipine- 
benazepril) is considered effective in treating congestive heart failure and pro- 
viding renal protection in patients with hypertension. 3 
Amlodipine, a dihydropyridine CCB with a slow onset and long duration of 
action, can inhibit the influx of extracellular calcium across vascular smooth- 
muscle cell membranes. The resulting decrease in intracellular calcium inhibits 
the contractile processes of myocardial smooth-muscle c lls, resulting in di- 
lation of the coronary and systemic arteries. 6 Benazepril hydrochloride is a 
prodrug hydrolyzed by esterase to the active metabolite benazeprilat. The 
latter has a long duration of action and decreases blood pressure by inhibit- 
ing angiotensin II production. 7 A capsule formulation* containing a combination 
of amlodipine 5 mg plus benazepril 10 mg was approved in March 1995 by the 
US Food and Drug Administration for the treatment of hypertension. Com- 
pared with amlodipine and benazepril monotherapy at the same doses, this 
combination is associated with a lower risk for edema nd a greater decrease 
in blood pressure. 8 
*Trademark: Lotrel ® (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey). 
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Tablet and capsule formulations are both commercially available. A tablet 
formulation* might have pharmacokinetic properties different from those of the 
capsule formulation. The tablet is scored and thus relatively easy to separate, 
if needed. If the relative bioavailability and pharmacokinetic properties are com- 
parable between the 2 formulations, pharmaceutical manufacturers would have 
an additional choice in generic drug development, and physicians could choose 
which formulation would be most appropriate in individual patients. However, 
the bioavailabilities of differing formulations may vary. 
The purpose of this study was to compare the relative bioavailability (ie, the 
rate and extent of absorption) and tolerability of the tablet versus the capsule 
formulation of combination amlodipine-benazepril in healthy volunteers. 
SUBJECTS AND METHODS 
This study was conducted from May 5, 2002, to June 8, 2002, at the Clinical Trial 
Center of the National Taiwan University Hospital, Taipei, Taiwan. The study 
protocol was reviewed and approved by the institutional review board (IRB) at 
the hospital. The IRB was to be informed of any serious or unexpected AEs that 
might affect the safety of the subjects or the conduct of the trial. All experi- 
ments complied with the Good Clinical Practice guidelines. 
Inclusion and Exclusion Criteria 
Healthy male volunteers aged ___18 years with normotension were recruited 
from the general population. 
Subjects were excluded from the study if findings on physical examination, 
biochemistry (blood urea nitrogen, serum creatinine concentration), urinaly- 
sis, or hematology were abnormal. Patients were excluded if they had received 
any other medications within 14 days before the study. We did not perform 
pharmacogenomic analyses of metabolic rates/differences or determine acety- 
lator status. 
All subjects provided written informed consent, underwent complete screen- 
ing including laboratory analysis, and were randomized 1 week before the start 
of the study. 
Study Drug Administration 
A single-dose, 2-sequence, 2-period, open-label, crossover design was used. 
Subjects were randomly assigned, using a computer-generated list of random 
numbers, to 1 of 2 treatment sequences: a single-dose tablet containing am- 
lodipine 5 mg plus benazepril 10 mg, followed by a single-dose capsule contain- 
ing the same dose of each drug (AB), or vice versa (BA). Both treatments were to 
be received after a 10-hour overnight fast. The treatment period for each drug 
consisted of dosing and pharmacokinetic analysis on day 1, followed by pharma- 
*Trademark: Latrel, Amtrel ® (1-FY Biopharm Co., Ltd., Taipei, Taiwan). 
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cokinetic analysis on days 2 to 7. The 2 treatment periods were separated by a 
4-week washout period. 
Nicotine, alcohol, and caffeine use was not permitted for at least 48 hours 
before and during the study. Other medications and strenuous exercise were 
not allowed during the study. On the day of study drug administration i  both 
treatment periods, lunch and dinner were provided to all subjects at the same 
times of day and were of similar caloric and fat content and distribution. 
Qualified health care professionals attended to the subjects throughout the study. 
Laboratory Analysis 
For the purposes of serial blood sampling for pharmacokinetic analysis, sub- 
jects remained at the hospital for 12 hours after dosing, and returned to the 
hospital on the morning and evening of study day 2 and on the evenings of days 
3 to 7. Specifically, blood samples were obtained before dosing and at 20, 40, 
60, 80, and 100 minutes and 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 60, 84, 108, 132, and 
156 hours after dosing. The samples were drawn by a nurse using a needle stick 
or IV cannula. If a cannula was used, it was inserted into an arm vein within 
5 minutes before dosing and was maintained using isotonic saline for flushing. 
immediately after samples were obtained, they were centrifuged at 4°C at 
-3000 rpm for 10 minutes, and the plasma was transferred to appropriately 
labeled polypropylene tubes. Samples were frozen in an upright position at 
-20°C and stored at this temperature until shipment o a central aboratory 
(Protech Pharmaservices Corporation, Taipei, Taiwan) for assay. 
Assessment ofAEs on each study day included subject interview, spontaneous 
reporting, laboratory analysis, physical examination, and electrocardiography. 
A sensitive, specific, accurate, reproducible liquid chromatography/mass 
spectrometry/mass spectrometry (LC/MS/MS) method was used to determine 
plasma amlodipine and benazeprilat concentrations. 9 Recovery studies were 
conducted to validate the analytical procedure based on the primary perfor- 
mance characteristics (precision, accuracy [including within-run and between- 
run variation], linearity, specificity, reproducibility, and limit of quantification). 
The lower limits of quantification ofamlodipine and benazeprilat chieved were 
0.1 and 0.2 ng/mL, respectively. Recovery and reproducibility assessment indi- 
cated good precision. Peak area ratios were used for calculation, and the cali- 
bration curve was fitted to a weighted (l/x) linear regression model; the linear- 
ity of this procedure was indicated by an average correlation coefficient of 
->0.998. The coefficient of variation (CV) of concentrations in the calibration 
curves ranged from 1.0% to 8.9% in the plasma samples. The relative errors of 
the concentrations in the calibration curves ranged from -5.2% to 9.5%. 
Pharmacokinetic Analysis 
Plasma concentration-time data for amlodipine and benazeprilat were tabu- 
lated and graphically displayed for each subject (data not shown). These data 
are presented as mean (SD). Based on these data, Cma x, Tmax, AUC0_t, AUC0_~, tl/2, 
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and the elimination rate constant (ke) were calculated using standard noncom- 
partmental  analytical methods. The k e value was determined using simple linear 
regression based on the terminal phase of plasma concentration. AUC0_ t was 
determined using the trapezoidal rule. AUC0_ ~ was determined using the trape- 
zoidal rule and extrapolated to infinity using an estimate of the last quantifiable 
concentrat ion divided by k e. The tl/2 value was estimated using (0.693/ke). 
AUC0_ ~ at (first) moment (AUMC0_~) was determined using the trapezoidal rule 
and extrapolated to infinity using the following equation: 
AUMC0-~ = Cntn/ke + Cn/ke2 + ~[(tn - tn - 1) x (C n _ ltn _ 1 + Cntn)/2]' 
where C n is the plasma drug concentrat ion, t n is the time point, t n _ 1 is the pre- 
vious t ime point, and C n _ 1 is the plasma drug concentrat ion at the previous 
t ime point. 
Mean residence time (MRT) was determined using the following equation: 
MRT = AUMC0_~/AUC0_ ~ 
The comparat ive bioavailability of the tablet and capsule formulations was 
summarized using the relative rate of absorption, comparing the amlodipine 
and benazepri lat Cma x values and MRTs and the ratio of the AUC. 
Statistical Analysis 
Given a 20% bioequivalence limit, a 3% difference in concentration-t ime 
data between the 2 formulations, and an estimated CV of 15%, 12 subjects would 
be required to achieve an 80% power at the 5% nominal level, based on 
Schuirmann's 2 one-sided test procedures using a 2 × 2 crossover design. 9
For each of the derived parameters,  summary statistics (n, mean, median, 
SD, minimum, maximum, and CV) were calculated. Comparisons between the 
2 formulations were made using the mean of the raw data of these parameters.  
For AUC and Cma x comparisons, we used log-transformed (In) data due to a 
skewed distribution. For MRT and tl/2, the means of the raw data were com- 
pared using the Student test. Continuous variables were analyzed using analy- 
sis of variance for the crossover design. The Wilcoxon Mann-Whitney test was 
used for the nonparametr ic  method if the distribution was not normal, such as 
that of Tma x. The 90% CI between the 2 dosing formulations was assessed. Based 
on the plasma concentrat ion-t ime data, the pharmacokinetic parameters were 
determined with noncompartmental  methods using WinNonlin Professional 
version 3.1 (Pharsight Corporation, Palo Alto, California). 
RESULTS 
Twelve healthy, male, Taiwanese subjects part ic ipated in the study (mean [SD] 
age, 23.5 [1.7] years [range, 21-27 years]; mean [SD] body weight, 65.7 [8.5] kg 
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[range, 57-73 kg]; mean [SD] height, 171.4 [4.6] cm [range, 157.0-177.8 cm]; 
mean [SD] body mass index, 22.39 [2.25] kg/m 2 [range, 18.25-25.96 kg/m2]). 
No statistically significant differences in Cmax, Tmax, ln(AUC0_t), ln(AUC0_~), 
MRT, or tl/2 were found between the 2 formulations (Table I). The 90% CIs for 
the rate and extent of absorption (ln[AUC0_t], ln[AUC0_~], and ln[Cmax] ) of the 
tablet versus the capsule were between 80% and 125%. The mean (SD) relative 
bioavailabilities, as represented by AUC0_ ~, of amlodipine and benazeprilat for 
tablets versus capsules were 1.060 (0.170) versus 0.949 (0.197), respectively. 
The mean plasma concentration-time profiles of amlodipine and benazeprilat 
were graphically similar (Figure). 
No clinically significant changes in vital signs, physical examination findings, 
laboratory parameters, or electrocardiography were found. No clinical AEs were 
observed. 
DISCUSSION 
This comparative bioavailability study suggests that single-dose tablets and 
capsules of combination amlodipine-benazepril had statistically similar phar- 
macokinetic properties in healthy, male, Taiwanese subjects. No statistically 
significant differences in Cma x or Tma x were found between the 2 formulations, 
suggesting that the rate of absorption of the tablets was similar to that of 
the capsules. The 90% CIs for the rate and extent of absorption (ln[AUC0_t], 
ln[AUC0_~], and ln[Cmax] ) of the tablets versus the capsules were between 80% 
and 125%, suggesting bioequivalence. No significant differences in MRT or tl/2 
were found between the 2 formulations, indicating that the retention time and 
elimination rate were statistically similar between them. Moreover, no clinical 
AEs were observed uring the study. 
The values for the pharmacokinetic properties obtained from the healthy 
volunteers in the present study were comparable to those reported Previously 
for amlodipine and benazeprilat (Table |1).10-12 The Tma x and tl/2 of amlodipine 
achieved with a single capsule in the present study were similar to findings 
in previous studies, indicating that the absorption and elimination rates in the 
present study were similar to those achieved in previous studies. In our 
study of amlodipine 5 mg and benazepril 10 mg, the amlodipine bioavailability 
measures were half of those found in the study by Faulkner et al, 1° in which 
amlodipine 10 mg was administered to white male volunteers. Consequently, it 
might be concluded that the bioavailability of amlodipine is similar in Taiwanese 
compared with white volunteers. 
The Cma~, Tmax, and AUC0_ t of benazeprilat achieved with the capsule in the 
present study were similar to those found in previous tudies) 1,12 However, sig- 
nificant differences in tl/2 were found between 3 studies (all, P < 0.05), with the 
highest values occurring in the study by Kaiser et al) 2 Thus, it could be postu- 
lated that the longer the sampling time, the more compartments could be seen 
in the profile of benazeprilat, which was used to calculate the tl/2. In the study 
by Kaiser et al, 12 the mean sampling time was 22.3 hours. 
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Mean (SE) plasma concentrations of (A) amlodipine and (B) benazeprilat (the 
active metabolite of benazepril) before (time 0; baseline) and after single 
dosing with a tablet and capsule formulation of combination amlodipine 5 mg 
plus benazepril 10 mg in healthy volunteers. 
Oral amlodipine is slow acting but is almost completely absorbed in the 
gastrointestinal tract, and in one study, the absolute bioavailability after oral 
administration was found to be relatively high in healthy volunteers (mean 
Cmax, --<5.9 ng/mL). 1° In another study, AUC, Cmax, and Tma x were consistently 
stable. 13 Due to extensive distribution and relatively slow clearance, amlodi- 
pine has been found to have a long tl/2, ranging from 31 to 50 hours. 10,13,14 
Benazepril has been found to be absorbed from the gastrointestinal tract and 
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then converted to benazeprilat. 15 The mechanisms of action have been 
shown to be mainly via hepatic metabolism, and conversion to be virtually 
complete after 4 hours, with consistently stable pharmacokinetic properties. 12
One previous clinical trial 16 assessed the tolerability of the oral combination 
amlodipine-benazepril in >1600 patients with hypertension; >500 of these 
patients were treated for ---6 months and >400 were treated for >1 year. The 
reported AEs were generally mild and transient, and no correlation with age, 
sex, race, or duration of therapy was found. In the present study, no AEs were 
observed, perhaps due to the small sample size. 
Sun et a111 found that the rate and extent of absorption of amlodipine and 
benazepril in oral combination therapy were not statistically different from 
those of either drug used alone. Sun et a111 also studied the pharmacokinetic 
interaction between amlodipine and benazepril in 12 healthy male subjects. 
Single doses of amlodipine 5 mg and benazepril 10 mg were orally administered 
alone or in combination according to a 3-way, Latin square, randomized, cross- 
over design. Our results, echoing those of Sun et al, 11 indicated no pharma- 
cokinetic interaction between the 2 drugs. 
CONCLUSIONS 
The results of this bioavailability comparison study in this population of 
healthy, male, Taiwanese volunteers suggest hat the tablet and capsule formu- 
lations of combination amlodipine-benazepril a ebioequivalent. Both formula- 
tions were well tolerated. 
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